ATE413163T1 - Granulierte formulierung des rapamycinesters ccl- 779 - Google Patents

Granulierte formulierung des rapamycinesters ccl- 779

Info

Publication number: ATE413163T1
Authority: AT; Austria
Prior art keywords: rapamycinester; ccl; granulated formulation; granulated; formulation
Prior art date: 2002-09-17

Application number

AT03754672T

Other languages

English (en)

Inventor

Muhammad Ashraf

Eric Benjamin

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-17

Filing date

2003-09-15

Publication date

2008-11-15

2003-09-15 Application filed by Wyeth Corp filed Critical Wyeth Corp

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE413163T1 publication Critical patent/ATE413163T1/de

Links

238000009472 formulation Methods 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
CBPNZQVSJQDFBE-HXVVJGEPSA-N ccl-779 Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-HXVVJGEPSA-N 0.000 title 1
PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 abstract 1
CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
229960002930 sirolimus Drugs 0.000 abstract 1
239000007787 solid Substances 0.000 abstract 1
229960000235 temsirolimus Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Oncology (AREA)
Hematology (AREA)
Transplantation (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cosmetics (AREA)

AT03754672T 2002-09-17 2003-09-15 Granulierte formulierung des rapamycinesters ccl- 779 ATE413163T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41126402P	2002-09-17	2002-09-17

Publications (1)

Publication Number	Publication Date
ATE413163T1 true ATE413163T1 (de)	2008-11-15

Family

ID=32030658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03754672T ATE413163T1 (de)	2002-09-17	2003-09-15	Granulierte formulierung des rapamycinesters ccl- 779

Country Status (24)

Country	Link
US (1)	US20040077677A1 (de)
EP (1)	EP1635830B1 (de)
JP (1)	JP2006506353A (de)
KR (1)	KR20050084559A (de)
CN (1)	CN100415233C (de)
AT (1)	ATE413163T1 (de)
AU (1)	AU2003272489B2 (de)
BR (1)	BR0314397A (de)
CA (1)	CA2496332A1 (de)
CR (1)	CR7791A (de)
DE (1)	DE60324609D1 (de)
DK (1)	DK1635830T3 (de)
EC (1)	ECSP055731A (de)
ES (1)	ES2315530T3 (de)
IL (1)	IL166824A0 (de)
MX (1)	MXPA05002828A (de)
NO (1)	NO20050836L (de)
NZ (1)	NZ538781A (de)
PT (1)	PT1635830E (de)
RU (1)	RU2326654C2 (de)
SI (1)	SI1635830T1 (de)
UA (1)	UA81265C2 (de)
WO (1)	WO2004026280A2 (de)
ZA (1)	ZA200502220B (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR0307544A (pt)	2002-02-01	2004-12-07	Ariad Gene Therapeutics Inc	Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
AR042938A1 (es) *	2003-02-06	2005-07-06	Wyeth Corp	Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20040258662A1 (en) *	2003-04-22	2004-12-23	Wyeth	Antineoplastic agents
MXPA05013865A (es) *	2003-07-25	2006-02-28	Wyeth Corp	Formulaciones liofilizadas de cci-779.
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
AU2004270154A1 (en) *	2003-09-03	2005-03-17	Wyeth	Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1701698T3 (da) *	2004-01-08	2008-05-05	Wyeth Corp	Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779
US7349971B2 (en) *	2004-02-05	2008-03-25	Scenera Technologies, Llc	System for transmitting data utilizing multiple communication applications simultaneously in response to user request without specifying recipient's communication information
CA2564811A1 (en)	2004-04-14	2005-10-27	Wyeth	Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006050461A1 (en)	2004-10-28	2006-05-11	Wyeth	Use of an mtor inhibitor in treatment of uterine leiomyoma
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2596392A1 (en) *	2005-02-15	2006-08-24	Wyeth	Orally bioavailable cci-779 tablet formulations
WO2007056175A2 (en) *	2005-11-04	2007-05-18	Wyeth	41-methoxy isotope labeled rapamycin 42-ester
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
CN102579467A (zh)	2005-11-14	2012-07-18	阿里亚德医药股份有限公司	雷帕霉素衍生物在治疗癌症中的用途
CA2669415A1 (en) *	2006-11-14	2008-05-22	Ariad Pharmaceuticals, Inc.	Solid dosage form comprising ap23573
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080175887A1 (en)	2006-11-20	2008-07-24	Lixiao Wang	Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
AR065802A1 (es) *	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
TW200901989A (en) *	2007-04-10	2009-01-16	Wyeth Corp	Anti-tumor activity of CCI-779 in papillary renal cell cancer
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
EP2245165A4 (de)	2008-01-11	2011-06-01	Massachusetts Eye & Ear Infirm	Transgene konditionalstopp-dimerisierbare-caspase-tiere
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
BRPI0912014A2 (pt)	2008-05-09	2019-03-06	Grünenthal GmbH	processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
AU2009270768A1 (en) *	2008-07-18	2010-01-21	Valeant Pharmaceuticals International	Modified release formulation and methods of use
WO2010024898A2 (en)	2008-08-29	2010-03-04	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
RU2015138422A (ru)	2009-07-22	2018-12-25	Грюненталь Гмбх	Стабильная при окислении, прочная на излом лекарственная форма
CN102573805A (zh)	2009-07-22	2012-07-11	格吕伦塔尔有限公司	热熔挤出的控制释放剂型
US9579285B2 (en)	2010-02-03	2017-02-28	Gruenenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of an extruder
JP2013527223A (ja)	2010-06-02	2013-06-27	フレゼニウス・カビ・オンコロジー・リミテッド	ラパマイシンエステルの安定な医薬組成物
BR112013005234A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo um polímero aniônico.
NZ607392A (en)	2010-09-02	2015-03-27	Gruenenthal Chemie	Tamper resistant dosage form comprising inorganic salt
US20120303115A1 (en) *	2011-05-25	2012-11-29	Dadino Ronald C	Expandable devices coated with a rapamycin composition
PE20141638A1 (es)	2011-07-29	2014-11-22	Gruenenthal Chemie	Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
RS56527B1 (sr)	2011-07-29	2018-02-28	Gruenenthal Gmbh	Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en)	2012-04-18	2018-11-19	Gruenenthal Gmbh	MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP6445537B2 (ja)	2013-05-29	2018-12-26	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	１個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
AR096439A1 (es)	2013-05-29	2015-12-30	Gruenenthal Gmbh	Forma de dosificación resistente al uso indebido que contiene una o más partículas
US10624862B2 (en)	2013-07-12	2020-04-21	Grünenthal GmbH	Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10682415B2 (en)	2013-07-22	2020-06-16	Wisconsin Alumni Research Foundation	Thermogel formulation for combination drug delivery
AU2014356581C1 (en)	2013-11-26	2020-05-28	Grunenthal Gmbh	Preparation of a powdery pharmaceutical composition by means of cryo-milling
MX2016014738A (es)	2014-05-12	2017-03-06	Gruenenthal Gmbh	Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es)	2014-05-26	2017-02-22	Gruenenthal Gmbh	Multiparticulas protegidas contra vertido de dosis etanolico.
JP2018517676A (ja)	2015-04-24	2018-07-05	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	即時放出および溶媒抽出に対する耐性を有する改変防止製剤
WO2017038925A1 (ja) *	2015-09-03	2017-03-09	日本化薬株式会社	ラパマイシン又はその誘導体を含有する医薬組成物
AU2016319203A1 (en)	2015-09-10	2018-02-22	Grünenthal GmbH	Protecting oral overdose with abuse deterrent immediate release formulations
WO2017129772A1 (en)	2016-01-29	2017-08-03	Xellia Phamaceuticals Aps	Stable pharmaceutical compositions of temsirolimus
KR102941613B1 (ko) *	2023-08-23	2026-03-19	광동제약 주식회사	안정성이 개선된 히노키티올을 함유하는 구강용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA737247B (en) *	1972-09-29	1975-04-30	Ayerst Mckenna & Harrison	Rapamycin and process of preparation
US3993749A (en) *	1974-04-12	1976-11-23	Ayerst Mckenna And Harrison Ltd.	Rapamycin and process of preparation
US5206018A (en) *	1978-11-03	1993-04-27	Ayerst, Mckenna & Harrison, Inc.	Use of rapamycin in treatment of tumors
US4885171A (en) *	1978-11-03	1989-12-05	American Home Products Corporation	Use of rapamycin in treatment of certain tumors
US4401653A (en) *	1981-03-09	1983-08-30	Ayerst, Mckenna & Harrison Inc.	Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) *	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5078999A (en) *	1991-02-22	1992-01-07	American Home Products Corporation	Method of treating systemic lupus erythematosus
US5080899A (en) *	1991-02-22	1992-01-14	American Home Products Corporation	Method of treating pulmonary inflammation
US5321009A (en) *	1991-04-03	1994-06-14	American Home Products Corporation	Method of treating diabetes
IL102414A (en) *	1991-07-25	1996-08-04	Univ Louisville Res Found	Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5286730A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory disease
US5286731A (en) *	1991-09-17	1994-02-15	American Home Products Corporation	Method of treating immunoinflammatory bowel disease
US5516781A (en) *	1992-01-09	1996-05-14	American Home Products Corporation	Method of treating restenosis with rapamycin
US5288711A (en) *	1992-04-28	1994-02-22	American Home Products Corporation	Method of treating hyperproliferative vascular disease
US5536729A (en) *	1993-09-30	1996-07-16	American Home Products Corporation	Rapamycin formulations for oral administration
IL111004A (en) *	1993-09-30	1998-06-15	American Home Prod	Oral formulations of rapamycin
US5362718A (en) *	1994-04-18	1994-11-08	American Home Products Corporation	Rapamycin hydroxyesters
TW403748B (en) *	1994-11-02	2000-09-01	Takeda Chemical Industries Ltd	An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5561138A (en) *	1994-12-13	1996-10-01	American Home Products Corporation	Method of treating anemia
US5496832A (en) *	1995-03-09	1996-03-05	American Home Products Corporation	Method of treating cardiac inflammatory disease
US5705190A (en) *	1995-12-19	1998-01-06	Abbott Laboratories	Controlled release formulation for poorly soluble basic drugs
CA2230748C (en) *	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US5989591A (en) *	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
US5985325A (en) *	1997-06-13	1999-11-16	American Home Products Corporation	Rapamycin formulations for oral administration
US6277983B1 (en) *	2000-09-27	2001-08-21	American Home Products Corporation	Regioselective synthesis of rapamycin derivatives
US20020013335A1 (en) *	2000-06-16	2002-01-31	American Home Products Corporation	Method of treating cardiovascular disease
TWI286074B (en) *	2000-11-15	2007-09-01	Wyeth Corp	Pharmaceutical composition containing CCI-779 as an antineoplastic agent
GB0123400D0 (en) *	2001-09-28	2001-11-21	Novartis Ag	Organic compounds
AU2003254168A1 (en) *	2002-07-30	2004-02-16	Wyeth	Parenteral formulations containing a rapamycin hydroxyester

2003
- 2003-09-15 DE DE60324609T patent/DE60324609D1/de not_active Expired - Lifetime
- 2003-09-15 JP JP2004537911A patent/JP2006506353A/ja active Pending
- 2003-09-15 US US10/663,506 patent/US20040077677A1/en not_active Abandoned
- 2003-09-15 PT PT03754672T patent/PT1635830E/pt unknown
- 2003-09-15 MX MXPA05002828A patent/MXPA05002828A/es active IP Right Grant
- 2003-09-15 ES ES03754672T patent/ES2315530T3/es not_active Expired - Lifetime
- 2003-09-15 NZ NZ538781A patent/NZ538781A/en unknown
- 2003-09-15 AT AT03754672T patent/ATE413163T1/de not_active IP Right Cessation
- 2003-09-15 KR KR1020057004555A patent/KR20050084559A/ko not_active Ceased
- 2003-09-15 EP EP03754672A patent/EP1635830B1/de not_active Expired - Lifetime
- 2003-09-15 CA CA002496332A patent/CA2496332A1/en not_active Abandoned
- 2003-09-15 SI SI200331456T patent/SI1635830T1/sl unknown
- 2003-09-15 WO PCT/US2003/029228 patent/WO2004026280A2/en not_active Ceased
- 2003-09-15 RU RU2005111222/15A patent/RU2326654C2/ru not_active IP Right Cessation
- 2003-09-15 CN CNB03822013XA patent/CN100415233C/zh not_active Expired - Fee Related
- 2003-09-15 BR BR0314397-0A patent/BR0314397A/pt not_active IP Right Cessation
- 2003-09-15 UA UAA200503586A patent/UA81265C2/uk unknown
- 2003-09-15 DK DK03754672T patent/DK1635830T3/da active
- 2003-09-15 AU AU2003272489A patent/AU2003272489B2/en not_active Ceased
2005
- 2005-02-10 IL IL16682405A patent/IL166824A0/xx unknown
- 2005-02-16 NO NO20050836A patent/NO20050836L/no not_active Application Discontinuation
- 2005-03-16 ZA ZA200502220A patent/ZA200502220B/en unknown
- 2005-04-08 CR CR7791A patent/CR7791A/es not_active Application Discontinuation
- 2005-04-13 EC EC2005005731A patent/ECSP055731A/es unknown

Also Published As

Publication number	Publication date
PT1635830E (pt)	2008-12-31
WO2004026280A3 (en)	2005-12-01
EP1635830A2 (de)	2006-03-22
KR20050084559A (ko)	2005-08-26
EP1635830B1 (de)	2008-11-05
US20040077677A1 (en)	2004-04-22
WO2004026280A2 (en)	2004-04-01
UA81265C2 (en)	2007-12-25
DK1635830T3 (da)	2009-02-23
MXPA05002828A (es)	2005-05-27
NO20050836L (no)	2005-04-15
CN1764459A (zh)	2006-04-26
RU2326654C2 (ru)	2008-06-20
AU2003272489A1 (en)	2004-04-08
DE60324609D1 (de)	2008-12-18
RU2005111222A (ru)	2005-09-20
NZ538781A (en)	2007-11-30
CA2496332A1 (en)	2004-04-01
ES2315530T3 (es)	2009-04-01
IL166824A0 (en)	2006-01-15
ZA200502220B (en)	2008-01-30
CR7791A (es)	2007-10-01
ECSP055731A (es)	2005-07-06
JP2006506353A (ja)	2006-02-23
SI1635830T1 (sl)	2009-02-28
HK1084050A1 (en)	2006-07-21
BR0314397A (pt)	2005-08-09
AU2003272489B2 (en)	2008-11-13
CN100415233C (zh)	2008-09-03

Legal Events

Date

Code

Title

Description

2009-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1635830

Country of ref document: EP

2010-12-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60324609D1 (de)	2008-12-18	GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
UA84881C2 (ru)	2008-12-10	Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
NO20050455L (no)	2005-02-09	Parenterale formuleringer inneholdende en rapamycinhydroksyester
ATE384061T1 (de)	2008-02-15	Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
NO20044599L (no)	2005-02-16	3-amino-tieno[2,3-b]pyridin-2-karboksysyreamid-forbindelser og fremgangsmater for fremstilling og anvendelser av dem
EA200601554A1 (ru)	2006-12-29	Замещенные индол-о-глюкозиды
AR031341A1 (es)	2003-09-17	Uso de cci-779 como agente antineoplastico
ECSP067098A (es)	2007-01-26	Compuestos y metodos para el tratamiento de dislipidemia
EP1783126A3 (de)	2008-11-26	N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten
DK1689233T3 (da)	2012-10-15	Bicykliske inhibitorer af MEK
DE60101000D1 (de)	2003-11-20	N-heterocyclische derivate als nos inhibitoren
MXPA06007829A (es)	2006-09-01	Composicion farmaceutica directamente comprimible para la administracion oral de 42-ester de rapamicina con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico.
DK1641803T3 (da)	2009-06-29	Thienopyrimidinderivater som kaliumkanalinhibitorer
WO2004054507A3 (en)	2005-02-10	Indolizine compounds
BRPI0414694A (pt)	2006-11-28	pró-fármaco(s) aciloximetilcarbamato de oxazolidinonas
CR7195A (es)	2004-03-05	Nuevos derivados de oxazolidinonas como antibacterianos
AR063310A1 (es)	2009-01-21	Procesos para la sintesis de isomeros individuales de cci-779 monopeg
BRPI0518079A (pt)	2008-11-04	usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
BRPI0408423A (pt)	2006-03-21	composições farmacêuticas compreendendo uma combinação de rapamicina ou seus derivados e pimecrolimus para o tratamento de doenças mediadas imunologicamente e por inflamação
ATE433450T1 (de)	2009-06-15	Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
UA83697C2 (ru)	2008-08-11	Cci-779 для лечения лимфомы из мантийных клеток